For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It’s completely free and we guarantee you’ll learn something new every day.
Private equity firms have amassed sizable stakes in countless glamorous businesses, from casinos lining the Vegas strip to professional sports teams. But some of the most alluring investments come from everyday places.
PE industry stalwart Blackstone Group has just agreed to buy the family owned Chamberlain Group — parent of top-of-the-line garage door opener purveyor, LiftMaster. The Wall Street Journal reported news of the deal Tuesday, which values the company at roughly $5 billion including debt.
While arguably not as hip as some of Blackstone’s digital investments like dating app suite Bumble or family history service Ancestry, Illinois-based Chamberlain’s garage door openers are relied on by millions of homes and businesses worldwide.
Owner of the LiftMaster, Chamberlain, Grifco, and Merlin brands, the firm’s myQ platform grants users garage door control via an app, useful for remote acceptance of food and grocery deliveries or to simply let the pet out for a stroll. And a partnership with Amazon launched in 2019 offers Prime customers in select cities packages delivered securely right into their garages. With a business model as reliable and adaptive as Chamberlain’s, Blackstone wants in for the long haul:
Top Casino Stocks For 2023: AVEO Pharmaceuticals, Inc.(AVEO)
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The companys pipeline of product candidates include Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors for renal cell carcinoma and other cancers; Ficlatuzumab, an anti-hepatocyte growth factor inhibitory antibody, which has completed Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380 Program, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia, which is a multi-factorial syndrome of involuntary weight loss associated with various cancers and diseases outside of cancer, including chronic kidney disease, congestive heart failure, and chronic obstructive pulmonary disease. It has strategic partnerships with Ophthotech Corporation; Biodesix, Inc.; St. Vincents Hospital Sydney Limited; Biogen Idec Inc.; and Kyowa Hakko Kirin. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.